See more : XTRA Bitcoin Inc. (CBTC) Income Statement Analysis – Financial Results
Complete financial analysis of Rezolute, Inc. (RZLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rezolute, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- INC S.A. (INC.WA) Income Statement Analysis – Financial Results
- MGC Pharmaceuticals Limited (MXC.L) Income Statement Analysis – Financial Results
- Chain Chon Industrial Co., Ltd. (5014.TWO) Income Statement Analysis – Financial Results
- Ningbo Huaxiang Electronic Co., Ltd. (002048.SZ) Income Statement Analysis – Financial Results
- JCK Hospitality Public Company Limited (JCKH.BK) Income Statement Analysis – Financial Results
Rezolute, Inc. (RZLT)
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 12.57M | 8.27M | 5.85M | 2.40M | 4.56M | 4.84K |
| Gross Profit | -36.00K | -382.00K | -256.00K | -303.00K | -18.00K | -48.00K | -1.07M | -12.57M | -8.27M | -5.85M | -2.40M | -4.56M | -4.84K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 55.74M | 43.81M | 32.49M | 14.99M | 14.45M | 19.08M | 17.28M | 12.09M | 9.45M | 4.70M | 34.32K | 3.49K | 0.00 |
| General & Administrative | 196.00K | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67M |
| Selling & Marketing | 14.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -42.63M |
| SG&A | 14.64M | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67K |
| Other Expenses | 0.00 | 0.00 | -231.00K | -515.00K | 0.00 | 321.00K | 136.13K | 37.14K | 5.33M | 3.51M | 11.30K | 295.00 | 6.62M |
| Operating Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 42.67K |
| Cost & Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 47.51K |
| Interest Income | 0.00 | 4.21M | 80.00K | 63.00K | 188.00K | 61.00K | 1.00K | 0.00 | 965.00 | 4.97K | 12.18K | 106.04K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.81M | 375.00K | 0.00 | 4.96M | 689.19K | 1.60K | 5.04K | 6.73K | 4.23M | 568.86K | 0.00 |
| Depreciation & Amortization | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 1.11M | 751.25K | 134.13K | 11.30K | 295.00 | 221.00 |
| EBITDA | -68.42M | -51.41M | -41.83M | -22.88M | -20.32M | -25.44M | -28.11M | -19.16M | -14.18M | -11.22M | -5.49M | -6.16M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -70.42M | -55.99M | -41.84M | -22.89M | -20.52M | -25.94M | -28.73M | -20.32M | -14.95M | -10.70M | -5.18M | -6.11M | -45.73K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.96M | 4.20M | 783.00K | 1.99M | 188.00K | -4.50M | -1.13M | 46.92K | 15.75K | -664.48K | -4.55M | -620.58K | -1.78K |
| Income Before Tax | -68.46M | -51.79M | -41.06M | -20.90M | -20.33M | -30.45M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -47.51K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -137.90K | -2.28M | 375.00K | -297.00 | -29.00K | 2.93M | -11.37K | -19.82K | 662.72K | 336.49K | 157.76K | 3.56K |
| Net Income | -68.46M | -51.79M | -38.78M | -21.28M | -20.33M | -30.42M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -49.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -1.01 | -2.13 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| EPS Diluted | -1.33 | -1.01 | -1.99 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| Weighted Avg Shares Out | 51.47M | 51.19M | 18.20M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
| Weighted Avg Shares Out (Dil) | 51.47M | 51.19M | 19.49M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as...
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded...
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in...
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday Biotech Sale: 12 Stocks for XBI-MAS." Despite overall market health, biotech stocks have significantly declined, with the XBI biotech index...
Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day
REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in BTIG's 3rd Annual Ophthalmology...
Rezolute Reports First Quarter Fiscal 2024 Results
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended...
Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study
Rezolute is a clinical-stage biotechnology company focused on metabolic diseases related to glucose control. Their lead asset, RZ358, is a monoclonal antibody being developed as a treatment for hyperinsulinism, a condition characterized by excessive insulin production. The Company is trading...
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical...
Source: https://incomestatements.info
Category: Stock Reports